How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

118 results for

"Zolpidem"

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Zolpidem

Zolpidem Top results for zolpidem - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for zolpidem The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

2. Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis Full Text available with Trip Pro

Quantitation of zolpidem in biological fluids by electro-driven microextraction combined with HPLC-UV analysis In this study, for the first time, an electro-driven microextraction method named electromembrane extraction combined with a simple high performance liquid chromatography and ultraviolet detection was developed and validated for the quantitation of zolpidem in biological samples. Parameters influencing electromembrane extraction were evaluated and optimized. The membrane consisted of 2 (...) was linear over the range of 10-1000 ng/mL for zolpidem (R2 >0.9991) with repeatability ( %RSD) between 0.3 % and 7.3 % (n = 3). The limits of detection and quantitation were 3 and 10 ng/mL, respectively. The sensitivity of HPLC-UV for the determination of zolpidem was enhanced by electromembrane extraction. Finally, the method was employed for the quantitation of zolpidem in biological samples with relative recoveries in the range of 60-79 %.

2018 EXCLI journal

3. Zolpidem tartrate - Insomnia, short-term treatment

Zolpidem tartrate - Insomnia, short-term treatment Common Drug Review CDEC Meeting — July 17, 2013; CDEC Reconsideration — September 18, 2013 Notice of CDEC Final Recommendation — September 25, 2013 Page 1 of 3 © 2013 CADTH CDEC FINAL RECOMMENDATION ZOLPIDEM TARTRATE (Sublinox – Meda Valeant Pharma Canada) Indication: Insomnia Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that sublingual zolpidem tartrate not be listed. Reason for the Recommendation: There is insufficient (...) evidence to determine if sublingual zolpidem provides comparable clinical benefit versus other hypnotics available in Canada for the treatment of acute, short-term insomnia. Background: Sublingual zolpidem is indicated for the short-term treatment and symptomatic relief of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The product monograph states that treatment with sublingual zolpidem should usually not exceed seven to 10

2013 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

4. Zolpidem: risk of drowsiness and reduced driving ability

Zolpidem: risk of drowsiness and reduced driving ability Zolpidem: risk of drowsiness and reduced driving ability - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Zolpidem: risk of drowsiness and reduced driving ability Taking zolpidem is associated with a risk of impaired driving ability the next day. Published 11 December 2014 From: Therapeutic area: Article date: May 2014 Zolpidem (Edluar, Stilnoct) is used to treat insomnia. Taking zolpidem is associated with a risk (...) of impaired driving ability the next day. To reduce this risk, advise patients: to take 10 milligrams of zolpidem at bedtime and not to take it again the same night not to drive, operate machinery, or work at heights until at least 8 hours after taking zolpidem not to take zolpidem with alcohol, illicit drugs, or other central nervous system suppressants not to drive, operate machinery or work at heights if they are still drowsy after taking Zolpidem People with liver impairment and the elderly should

2014 MHRA Drug Safety Update

5. Zolpidem

Zolpidem USE OF ZOLPIDEM IN PREGNANCY 0344 892 0909 USE OF ZOLPIDEM IN PREGNANCY (Date of issue: November 2013 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Zolpidem is a short-acting non-benzodiazepine hypnotic agent which acts (...) on benzodiazepine receptors. It is indicated in the short-term treatment of patients with debilitating insomnia, or where insomnia is causing severe distress. There are few data available concerning the use of zolpidem in human pregnancy. These data do not currently suggest an increased risk of congenital malformation but are considered too limited to state that no risk exists. Associations between in-utero zolpidem exposure and increased risks of preterm delivery and low birth weight have been reported

2014 UK Teratology Information Service

6. Intermezzo (zolpidem tartrate)

Intermezzo (zolpidem tartrate) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Intermezzo (zolpidem tartrate) Company: Transcept Pharmaceuticals, Inc. Application No.: 022328 Approval Date: 11/23/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2011 FDA - Drug Approval Package

7. Zolpidem and Uncontrollable Nocturnal Eating Binges

Zolpidem and Uncontrollable Nocturnal Eating Binges Zolpidem and Uncontrollable Nocturnal Eating Binges – Clinical Correlations Search Zolpidem and Uncontrollable Nocturnal Eating Binges February 24, 2010 4 min read John Cruz Faculty peer reviewed A number of studies have shown that zolpidem ( Ambien ), the most commonly prescribed sleep-inducing medication on the market, can produce uncontrollable nocturnal eating behavior among users. Sleep related eating disorder (SRED) is characterized (...) by partial arousals from sleep to ingest food, usually within the first three hours after sleep onset, occurring one to six times per night. 1 Patients describe an “automatic” inclination to eat and an inability to return to sleep unless they eat. The foods are often high in calories and ingested in massive quantities. 2 The occurrence of zolpidem-induced nocturnal eating is probably more common than currently reported. In a New York Times article 3 entitled “Study links Ambien use to unconscious food

2010 Clinical Correlations

8. Adding zolpidem to CBT produces limited benefits in persistent insomnia

Adding zolpidem to CBT produces limited benefits in persistent insomnia Adding zolpidem to CBT produces limited benefits in persistent insomnia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding zolpidem to CBT produces limited benefits in persistent insomnia Article Text Therapeutics Adding zolpidem to CBT produces limited benefits in persistent insomnia Statistics from Altmetric.com Question Question: Does the addition

2010 Evidence-Based Mental Health

9. Five Don'ts to Prevent Novel Coronavirus Infection (COVID-19) and Death - part 2

-benzodiazepines” are classified based on the structure. Because "non-benzodiazepines" or “z-drugs” also act as benzodiazepine receptor agonist, same as the structurally classified benzodiazepines, “Med Check" classify them (z-drugs) as benzodiazepines in terms of mechanism of action. I n a d d i t i o n t o t h e m o s t c o m m o n l y u s e d benzodiazepines (Note) such as Ambien (zolpidem), relatively new melatonin derivative ramelteon (trade name Rozerem) and the orexin receptor antagonist suvorexant

2020 Med Check - The Informed Prescriber

10. Canadian guidelines on benzodiazepine receptor agonist use disorder among older adults

agonists, novel benzodiazepine receptor agonists, or z-drugs (i .e ., zolpidem, zopiclone), do not . We use the term BZRAs for both . Our recommendations deal with all BRZAs as they have similar benefits, side effects, and risks . These drugs have regulatory approval for the management of anxiety and panic disorders, short-term treatment of insomnia, seizures, alcohol withdrawal, sedation, and spasticity . They are also often used in an off-label manner (i .e ., any use of a drug beyond what Health

2019 CPG Infobase

12. Insomnia

sleep (e.g., driving) Zolpidem Z-drug 22 min 11 min HRME Risk of next-day impairment, unawareness of activities during sleep (e.g., driving) 5 1 Reduction from placebo. 2 Increase from placebo. 3 HRME = high-risk medication in the elderly. 4 The only benzodiazepines FDA approved for insomnia are temazepam, flurazepam, and triazolam. 5 Women are at higher risk of impairment. 9 Pharmacologic options for refractory insomnia in adults Table 3 shows dosing information for medications that may be used (...) , passionflower Medication that causes rebound insomnia and next-day performance impairment • Diphenhydramine (Benadryl): The SmartPhrase .avsbenadrylnotrecomforinsomnia provides information to patients on why Benadryl is not recommended. Medications with significant harms • Z-drugs: zolpidem • Benzodiazepines: temazepam See the KPWA Benzodiazepine and Z-drug Safety Guideline for more information. Adverse effects of benzodiazepines and Z-drugs include: o Particularly high risk of overdose when combined

2019 Kaiser Permanente Clinical Guidelines

15. EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke

stroke? Chronic use of benzodiazepines and related drugs (BDZRs) (such as zopiclone and zolpidem) has been linked in several studies with increased risk of impaired cognitive function, dementia and mortality [93–96]. However, the e?ect of insomnia treatment on stroke risk has rarely been assessed. Results of literature search. • No systematic reviews were identi?ed. • Three primary studies (two of class II quality, one of class III) were included in our review of the evi- dence [97–99]. Overview

2020 European Academy of Neurology

17. Multimorbidity and polypharmacy

Guidelines Research T eam has produced a benzodiazepine and Z-drug deprescribing algorithm that supports recommendations in the NICE guidance on the use of zolpidem and zopiclone for the short-term management of insomnia, and medicines optimisation. Addressing inappropriate polypharmacy is a medicines optimisation priority that is supported by the work of the Regional Medicines Optimisation Committees (RMOCs). Practice examples and shared learning Primary Care Commissioning has published a collection

2017 National Institute for Health and Clinical Excellence - Advice

18. Health app: Sleepio for adults with poor sleep

appraisal guidance on zaleplon, zolpidem and zopiclone for the short-term management of insomnia states that the choice of management strategy depends on the presenting symptoms. Non-pharmacological interventions such as CBT have been shown to be effective in managing persistent insomnia. However, in practice, access to many of these therapies is restricted through a combination of a lack of trained providers, cost and a poor understanding of available options. Health app: Sleepio for adults with poor

2017 National Institute for Health and Clinical Excellence - Advice

19. Insomnia

: a systematic review and economic evaluation Dundar Y, Boland A, Strobl J, Dodd S, Haycox A, Bagust A, Bogg J, Dickson R, Walley T CRD summary This review compared zaleplon, zolpidem and zopiclone with benzodiazepines (...) (licensed and used in the UK) for the short-term management of insomnia . The authors concluded that short-acting drugs (Z-drugs) seemed equally effective and safe, but that there was a clear need for further research in this area. The authors suggested interpreting the findings (...) with considerable caution, and their recommendation for further research seems appropriate. Authors' objectives To compare the clinical and cost-effectiveness of zaleplon, zolpidem and zopiclone with benzodiazepines for the short 2004 17. Insomnia with objective short sleep duration is associated with longer duration of insomnia in the Freiburg Insomnia Cohort compared to insomnia with normal sleep duration, but not with hypertension. STUDY OBJECTIVES: To replicate the association between insomnia

2018 Trip Latest and Greatest

20. Temazepam

have questions please contact us via jon.brassey@tripdatabase.com Top results for temazepam 1. Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people. 25922426 2015 06 16 2016 03 11 2015 06 16 1461-7285 29 7 2015 Jul Journal of psychopharmacology (Oxford, England) J. Psychopharmacol. (Oxford) Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave (...) activity during sleep in healthy people. 764-76 10.1177/0269881115581963 Current pharmacological (...) treatments for insomnia include benzodiazepine and non-benzodiazepine hypnotics targeting γ-aminobutyric acid (GABA)A receptors, as well as agonists of the melatonin receptors MT1 and MT2. Melatonin, temazepam and zolpidem are thought to exert their effect through different mechanisms of action, but whether this leads to differential effects on electroencephalogram (EEG) power spectra during sleep

2018 Trip Latest and Greatest